Pleiotrophin: Analysis of the endothelialisation potential

Area of Science:

• Cardiovascular Diseases
• Biomaterials Science
• Cell Biology

Background:

• Endothelialisation of vascular substitutes is crucial for treating cardiovascular diseases but remains a significant challenge.
• Stromal Derived Factor 1 (SDF-1) is a known endothelialisation promoter.
• Pleiotrophin is a potential alternative, with its effects on endothelial cell proliferation and migration previously uninvestigated.

Purpose of the Study:

• To compare the efficacy of Pleiotrophin against SDF-1 in promoting endothelial cell proliferation and migration.
• To evaluate Pleiotrophin's potential as an endothelialisation promoter for vascular substitutes.

Main Methods:

• EA.hy926 endothelial cells were treated with Pleiotrophin (50 ng/ml) or SDF-1 (50 ng/ml).
• Cell viability was assessed using MTT assay.
• Cell migration was evaluated using Transwell chambers and scratch wound assays.
• Protein expression (CXCR4, RPTP β/ζ, PCNA, Rac1) was analyzed via Western Blot.

Main Results:

• Pleiotrophin significantly increased endothelial cell viability compared to SDF-1.
• Endothelial cell migration was notably enhanced by Pleiotrophin treatment relative to SDF-1.
• Western Blot analysis revealed Pleiotrophin upregulated RPTP β/ζ, PCNA, and Rac1 expression more than SDF-1.

Conclusions:

• Pleiotrophin demonstrates significant positive effects on endothelial cell viability, migration, and repair.
• These findings position Pleiotrophin as a promising candidate molecule for enhancing re-endothelialisation processes.
• Further research into Pleiotrophin's mechanisms could advance vascular graft technology.